GlassScriptPhysician profile
Scott W Cole
NPI 1346351004
$19,923.26
in general payments reported to CMS, 2019-2025
64 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,941 · 2021: $529 · 2022: $998 · 2023: $1,407 · 2024: $1,561 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862 · Education: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.21 |
| Education | $640.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $7,875.18 | 2019-2025 | |
| Heron Therapeutics, INC. | $4,914.35 | 2019-2020 | |
| Pfizer INC. | $1,035.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $690.95 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $610.43 | 2020-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $484.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $299.98 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $241.44 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $233.81 | 2019-2024 | Trodelvy |
| Amgen INC. | $219.23 | 2020-2023 | Xgeva, Nplate, Vectibix |
| Astellas Pharma US INC | $178.45 | 2020-2025 | Vyloy, Padcev |
| Mirati Therapeutics, INC. | $157.98 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $152.38 | 2024-2025 | Onivyde, Tazverik |
| Janssen Biotech, INC. | $150.62 | 2019-2025 | Erleada |
| Seagen INC. | $148.67 | 2020-2023 | Padcev |
Show all 62 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.